Physician profile
Jason Jaramillo
NPI 1700164183
$1,846.02
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $695 · 2021: $23.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $388.70 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $301.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $233.49 | 2019-2020 | |
| Amarin Pharma, INC. | $213.55 | 2019-2020 | |
| Novo Nordisk INC | $127.87 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $113.96 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $80.35 | 2019-2020 | |
| Amgen INC. | $60.19 | 2019 | |
| Genentech USA, INC. | $55.33 | 2019-2020 | |
| Abbvie INC. | $44.40 | 2019-2021 | |
| Lilly USA, LLC | $39.17 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.56 | 2019 | |
| Merck Sharp & Dohme LLC | $20.86 | 2020 | |
| Qiagen, LLC | $19.78 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $19.56 | 2020 | |
| Seqirus USA INC | $19.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.59 | 2020 | |
| Pfizer INC. | $12.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.91 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Jaramillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.